Drugs and Treatment Resources
Featured Centers
- Eating Out? Cut Calories, Heartburn
- 5 Good Ways to Save Money on Medicine
- 8 Ways to Treat Your Allergies
The respiratory syncytial virus (RSV), discovered in 1956, is capable of causing a broad spectrum of illnesses. Older children and adults will commonly e...
|
|
Medical Editor: John P. Cunha, DO, FACOEP
Synagis (palivizumab) is used to prevent serious lung disease caused by respiratory syncytial virus (RSV) in premature infants, and infants born with certain lung disorders or heart disease. It will not treat a child who is already sick with RSV disease. Synagis is a man-made antibody to RSV. Common side effects include diarrhea, fever, cough, earache, runny nose, or pain/redness/swelling at the injection site.
The recommended dose of Synagis is 15 mg per kg of body weight given monthly by intramuscular injection. The first dose of Synagis should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. There may be other drugs that can interact with Synagis. Tell your doctor about all the prescription and over-the-counter medications your child has received. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your child's doctor. Synagis is not indicated for adult usage. It is not known whether Synagis can cause fetal harm or could affect reproductive capacity when administered to a pregnant woman. Because this drug is not for adult use, it is not recommended while breast-feeding.
Our Synagis (palivizumab) Drug Center provides a comprehensive view of available drug information as well as related drugs, user reviews, supplements, and diseases and conditions articles.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD) [see Clinical Studies].
The following point should be considered when prescribing Synagis:
Read the complete drug monograph for Synagis »
Drug Description - Indications & Dosage - Side Effects & Drug Interactions - Warnings & Precautions - Contraindications - Medication Guide and More
What is Patient information?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Get emergency medical help if your child has any of these signs of an allergic reaction: hives; difficult breathing; swelling of the face, lips, tongue, or throat.
Call your doctor at once if your child has a serious side effect such as:
Read the complete patient information for Synagis »
Possible Side Effects - Images - What Is - How Should I Take It - What If I Miss a Dose - What Should I Avoid and More
What is Consumer information?
A concise overview of the drug for the patient or caregiver from First DataBank.
HOW TO USE: Read the Patient Information Leaflet provided by your doctor or pharmacist before your child starts receiving palivizumab and before each injection. If you have any questions, consult your doctor or pharmacist.
This medic...
Read the complete consumer information for Synagis »
Warnings - Uses - How to Use - Side Effects - Precautions - Drug Interactions and More
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.